Form 4: ARS Pharma CEO Sells 50,000 Shares Under 10b5-1 Plan
Insider Transaction Report
ARS Pharmaceuticals' President and CEO, Richard E. Lowenthal, sold 50,000 shares of common stock for approximately $14.49 per share under a pre-arranged trading plan.
Summary
- Richard E. Lowenthal, President and CEO, Director, and 10% owner of ARS Pharmaceuticals, Inc. (SPRY), sold 50,000 shares of common stock.
- The transaction occurred on August 21, 2025, at a weighted average price of $14.4869 per share, with prices ranging from $14.31 to $14.61.
- The sale was executed under a Rule 10b5-1 trading plan established on May 15, 2025.
- Following the transaction, Lowenthal's indirect beneficial ownership includes 1,196,494 shares via his Charitable Remainder UniTrust, 1,247,447 shares via his spouse's Charitable Remainder UniTrust (beneficial ownership disclaimed), and 8,859,200 shares via the Lowenthal-Tanimoto Family Trust.
Sentiment
Score: 5
Explanation: The sale by the CEO, while significant in volume, was conducted under a pre-arranged 10b5-1 plan, which mitigates the immediate negative signal often associated with insider selling. It's a planned liquidity event rather than a reaction to new, undisclosed negative information.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new information.
Negatives
- An insider, specifically the President and CEO, selling a significant number of shares (50,000) could be perceived negatively by the market, even if pre-planned.
Risks
- Potential negative market perception due to insider selling, which could lead to downward pressure on the stock price.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May interpret the CEO's sale as a lack of confidence, potentially leading to downward pressure on the stock price, despite the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 2006-04-03 | Date of Lowenthal-Tanimoto Family Trust U/A DTD |
| 2020-01-07 | Date of Richard E. Lowenthal Charitable Remainder UniTrust |
| 2020-01-07 | Date of Sarina Tanimoto Charitable Remainder UniTrust |
| 2025-05-15 | Date Rule 10b5-1 trading plan was entered into |
| 2025-08-21 | Date of common stock transaction |
| 2025-08-22 | Date of Form 4 signature |
Recommendation
holdWhile the CEO's sale of 50,000 shares is notable, it was executed under a pre-established Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to new, adverse company-specific information. This mitigates the negative signal typically associated with insider selling. Without additional context on the company's fundamentals or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments and the company's performance.
Keywords
ARS Pharmaceuticals, SPRY, Insider Sale, Form 4, Richard E. Lowenthal, CEO, 10b5-1 Plan, Stock Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.